Drugs / CaHMB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05869812 | May 2023 → Dec 2028 expected | muscular atrophy | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04701463 | Jan → Nov 2020 | obesity disorder, skin disorder | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CaHMB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05869812 ↗ |
| Known as | calcium beta-hydroxy-beta-methylbutyrate | “L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate” NCT04701463 ↗ |